PBLS

Parabilis Medicines, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$27.48

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.2 / %30

Non-compliant assets / Total market cap %1 / %30

Non-compliant income / Total income %97.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.